Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViiV Offers Entire HIV/AIDS Portfolio To Generic Firms In Low-Income Countries, No Royalties Attached

This article was originally published in The Pink Sheet Daily

Executive Summary

With the problem of public access to medicines largely overcome, the new challenge is to get the more high-tech therapies to people with HIV/AIDS in the least developed countries, a spokeswoman said.

You may also be interested in...

ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA

MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented

With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate

Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class

GSK And Pfizer Join Forces In New HIV-Focused Venture

ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts